GSK plc Sponsored ADR (GSK)
GSK slides 6% after US CDC narrows scope of RSV shots
GSK's shares dropped more than 6% on Thursday, a day after a U.S. public health agency narrowed its usage recommendation for all respiratory syncytial virus (RSV) vaccines and held off on recommending their use for those under 60 years of age.
US advisers to consider RSV shots as GSK looks to keep market lead
A committee of outside experts to the U.S. CDC are set to vote on whether to expand the age group of adults who should receive respiratory syncytial virus (RSV) vaccines this year, as GSK battles rival Pfizer and new entrant Moderna to keep its top position in the market.
GSK's Filing for Expanded Use of Jemperli Gets EMA Acceptance
The European Medicines Agency accepts GSK's application for the expanded use of Jemperli plus chemotherapy to include all adult patients with primary advanced or recurrent endometrial cancer.
GSK 100% backs London listing, says boss
GSK PLC (LSE:GSK, NYSE:GSK) has issued its support to the flagging London market, stating that it is “unequivocally, 100 per cent committed” to keeping its listing in the UK. Speaking at the Time CEO Summit, boss Emma Walmsley said that even though only 3 per cent of its business is in Britain, GSK switching its listing was "not a debate for us.
Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs
Cantor Fitzgerald has initiated coverage on Innoviva, Inc. INVA, citing the company's unique business model centered around royalties and healthcare assets.
Why GSK (GSK) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
GSK 'still appealing' despite US legal setback says broker
GSK PLC (LSE:GSK, NYSE:GSK) is 'still appealing' - even in the wake of a significant legal setback, according to regional broker Shore Capital, which set out its 'buy' case in the wake of the UK drug giant's decision to challenge a key US court ruling. The Delaware state court ruling allowed plaintiffs' expert testimony in Zantac trials, contrary to a previous Federal court decision dismissing all multi-district litigation (MDL) cases.
GSK appeals Delaware Zantac ruling
GSK PLC (LSE:GSK, NYSE:GSK) and other pharmaceutical companies asked a Delaware court to allow an appeal of a ruling permitting over 70,000 lawsuits claiming Zantac causes cancer. Analysts had expected the UK drug giant, along with Pfizer, Sanofi and Boehringer Ingelheim to contest the original ruling.
GSK's RSV Vaccine Arexvy Gets FDA Nod for Adults 50-59 Years
GSK's Arexvy becomes the first RSV vaccine approved for adults aged 50-59 who are at high risk.
GSK RSV jab receives label expansion from US regulator
GSK PLC (LSE:GSK, NYSE:GSK) has confirmed that the US Food & Drug Administration has approved Arexvy for preventing respiratory syncytial virus (RSV) in adults aged 50 to 59 at increased risk of severe outcomes from the cold-like infection. GSK estimates over 13 million US adults fall into this category.
FDA approves GSK's RSV vaccine for high-risk adults ages 50 to 59, expanding shot's reach
The Food and Drug Administration expanded the approval of GSK's respiratory syncytial virus vaccine to adults ages 50 to 59 who are at increased risk of getting severely sick from the virus. The agency first approved GSK's jab in May 2023 for patients 60 and above, who are more vulnerable to severe cases of the virus.
US FDA expands GSK's RSV vaccine approval to adults aged 50 to 59
The U.S. Food and Drug Administration approved the expanded use of GSK's respiratory syncytial virus vaccine on Friday in adults aged between 50 and 59, making it the first shot endorsed for that age group.
